Discriminating hepatocellular carcinoma from metastatic carcinoma on fine-needle aspiration biopsy of the liver: The utility of immunocytochemical panel

Diagnostic Cytopathology

Volumn 37, Issue 3, 2009, Pages 184-190

  Saleh, Husain A ^a,c   Aulicino, Michael ^a   Zaidi, Sayed Y ^a   Khan, Aurang Zeb ^a   Masood, Shahla ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^c SINAI GRACE HOSPITAL   (United States)

Author keywords

Fine needle aspiration; Hepatocellular carcinoma; Immunocytochemistry; Liver; Metastatic adenocarcinoma

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 20; CYTOKERATIN 7; GLYPICAN 3; PROTEINASE ACTIVATED RECEPTOR 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; COLON CANCER; CONTROLLED STUDY; CYTODIAGNOSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; KIDNEY CANCER; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER METASTASIS; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; STOMACH CANCER; ADENOCARCINOMA; LIVER TUMOR; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; STATISTICAL MODEL;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA, HEPATOCELLULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; TUMOR MARKERS, BIOLOGICAL;

EID: 64249139333     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20982     Document Type: Article

References (26)

1. Renshaw AA, Haja J, Wilbur DC, Miller TR; Cytology Committee College of American Pathologists. Fine-needle aspirates of hepatocellular carcinoma that are misclassified as adenocarcinoma: Correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Arch Pathol LabMed2006;130:19-22.
2. Renshaw AA, Haja J, Wilbur DC, Miller TR; Cytology Committee, College of American Pathologists. Fine-needle aspirates of adenocarcinoma/metastatic carcinoma that resemble hepatocellular carcinoma: Correlating cytologic features and performance in the College of American Pathologists Nongynecologic Cytology Program. Arch Pathol Lab Med 2005;129:1217-1221.
3. Das DK. Cytodiagnosis of hepatocellular carcinoma in fine-needle aspirates of the liver: Its differentiation from reactive hepatocytes and metastatic adenocarcinoma. Diagn Cytopathol 1999;21:370.
4. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: An immunohistochemical comparison to carcinoembryonic antigen CD 10, and α-fetoprotein. Am J Surg Pathol 2002;26:978-988.
5. Lau SK, Prakash S, Geller SA, Alsabeh R. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002;33:1175-1181.
6. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006; 14:266-272.
7. Morrison C, Marsh W Jr, Frankel WL. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol 2002; 15:1279-1287.
8. Proca DM, Niemann TH, Porcell AI, DeYoung BR. MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. Appl Immunohistochem Mol Morphol 2000;8:120-125.
9. Sharifi S, Hayek J, Khettry U, Nasser I. Immunocytochemical staining of Kupffer and endothelial cells in fine needle aspiration cytology of hepatocellular carcinoma. Acta Cytol 2000; 44:7-12.
10. Wang L, Vuolo M, Suhrland MJ, Schlesinger K. HepParl, MOC- 31, pCEA, mCEA and CD 10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates. Acta Cytol 2006;50:257-262.
11. Onofre AS, Pomjanski N, Buckstegge B, Böcking A. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Cancer 2007; 111:259-268.
12. Gottschalk-Sabag S, Ron N, Glick T. Use of CD34 and factor VIII to diagnose hepatocellular carcinoma on fine needle aspirates. Acta Cytol 1998;42:691-696.
13. Bedrossian CW, Davila RM, Merenda G. Immunocytochemical evaluation of liver fine-needle aspirations. Arch Pathol Lab Med 1989;113:1225-1230.
14. Gokden M, Shinde A. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver. Diagn Cytopathol 2005;33:166-172.
15. Onofre AS, Pomjanski N, Buckstegge B, Böcking A. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Cancer 2007; 111:259-268.
16. Zimmerman RL, Burke MA, Young NA, Solomides CC, Bibbo M. Diagnostic value of hepatocyte paraffin 1 antibody to discriminate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsies of the liver. Cancer 2001;93:2.
17. Siddiqui MT, Saboorian MH, Gokaslan ST, Ashfaq R. Diagnostic utility of the HepParl antibody to differentiate hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration samples. Cancer 2002;96:49.
18. Kakar S, Gown AM, Goodman ZD, Ferrell LD. Best practices in diagnostic immunohistochemistry: Hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med 2007;131:1648-1654.
19. Coston WM, Loera S, Lau SK, et al. Distinction of hepatocellular carcinoma from benign hepatic mimickers using glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol 2008;32:433-444.
20. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
21. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006;30:1405-1411.
22. Ligato S, Mandich D, Cartun RW. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: An immunocytochemical study. Mod Pathol 2008;21:626-631.
23. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-564.
24. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: Diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441.
25. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: A novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer 2007;lll:316-322.
26. Saad RS, Luckasevic TM, Noga CM, Johnson DR, Silverman JF, Liu YL. Diagnostic value of HepParl, pCEA, CD10, and CD34 expression in separating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration cytology. Diagn Cytopathol 2004;30:l-6.